Literature DB >> 24576679

Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia.

Elson Asevedo1, Lucas B Rizzo2, Ary Gadelha3, Rodrigo B Mansur4, Vanessa K Ota5, Arthur A Berberian6, Bruno S Scarpato7, Antônio L Teixeira8, Rodrigo A Bressan9, Elisa Brietzke10.   

Abstract

Although several studies have pointed to a possible role of interleukin 2 (IL-2) in schizophrenia (SZ), association between IL-2 and the different groups of symptoms has not been explored. The objective of this study was to investigate a possible correlation of peripheral IL-2 levels with symptoms and cognitive performance in patients with SZ. In addition, we compared the plasma levels of IL-2 between patients with SZ and healthy controls. Twenty-nine chronically medicated outpatients with SZ according to DSM-IV were compared with twenty-six healthy controls. The patients were evaluated with the Positive and Negative Syndrome Scale (PANSS), the Calgary Depression Scale for Schizophrenia (CDSS), the Clinical Global Impression (CGI) and the Global Assessment of Functioning (GAF). All the participants had blood collected into EDTA tubes by venipuncture between 9:00 and 10:00AM. Plasma concentrations of IL-2 were determined by cytometric bead array. A computerized neuropsychological battery assessed verbal learning, verbal fluency, working memory, set shifting, executive function, inhibition and intelligence. Patients with SZ had lower levels of IL-2 than healthy controls (p<0.001). In the SZ group, IL-2 levels were positively correlated with scores in the digit span test (rho=0.416, P=0.025) and intelligence (rho=0.464, P=0.011). We also found a negative correlation between IL-2 and total score in the negative subscale of PANSS (rho=-0.447, p=0.015). Our findings suggest that IL-2 may be involved in the mechanisms related to cognitive deterioration and negative symptomatology in schizophrenia.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Behavioral symptoms; Biological markers; Cognition; Interleukin-2; Schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 24576679     DOI: 10.1016/j.physbeh.2014.02.032

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  73 in total

Review 1.  Gastrointestinal regulation of food intake.

Authors:  David E Cummings; Joost Overduin
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  Divergent leptin signaling in proglucagon neurons of the nucleus of the solitary tract in mice and rats.

Authors:  Lihong Huo; Kevin M Gamber; Harvey J Grill; Christian Bjørbaek
Journal:  Endocrinology       Date:  2007-11-01       Impact factor: 4.736

Review 3.  Homeostatic and hedonic signals interact in the regulation of food intake.

Authors:  Michael Lutter; Eric J Nestler
Journal:  J Nutr       Date:  2009-01-28       Impact factor: 4.798

Review 4.  Central control of body weight and appetite.

Authors:  Stephen C Woods; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

5.  Leptin and the control of food intake: neurons in the nucleus of the solitary tract are activated by both gastric distension and leptin.

Authors:  Lihong Huo; Lisa Maeng; Christian Bjørbaek; Harvey J Grill
Journal:  Endocrinology       Date:  2007-02-22       Impact factor: 4.736

6.  Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.

Authors:  Diana L Williams; Denis G Baskin; Michael W Schwartz
Journal:  Endocrinology       Date:  2008-12-12       Impact factor: 4.736

7.  Orexin signaling in the ventral tegmental area is required for high-fat appetite induced by opioid stimulation of the nucleus accumbens.

Authors:  Huiyuan Zheng; Laurel M Patterson; Hans-Rudolf Berthoud
Journal:  J Neurosci       Date:  2007-10-10       Impact factor: 6.167

Review 8.  Gut peptides in the control of food intake.

Authors:  T H Moran
Journal:  Int J Obes (Lond)       Date:  2009-04       Impact factor: 5.095

9.  Orexin-A hyperphagia: hindbrain participation in consummatory feeding responses.

Authors:  John-Paul Baird; Angela Choe; Jasmine L Loveland; Janine Beck; Carrie E Mahoney; Julia S Lord; Lindsay A Grigg
Journal:  Endocrinology       Date:  2008-11-13       Impact factor: 4.736

10.  Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake.

Authors:  Darleen A Sandoval; Didier Bagnol; Stephen C Woods; David A D'Alessio; Randy J Seeley
Journal:  Diabetes       Date:  2008-05-16       Impact factor: 9.461

View more
  15 in total

1.  Can anti-inflammatory medications improve symptoms and reduce mortality in schizophrenia?

Authors:  Maju Mathew Koola; Jeffrey K Raines; Robert G Hamilton; Robert P McMahon
Journal:  Curr Psychiatr       Date:  2016-04-25

Review 2.  Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.

Authors:  Chi-Yu Lai; Elizabeth Scarr; Madhara Udawela; Ian Everall; Wei J Chen; Brian Dean
Journal:  World J Psychiatry       Date:  2016-03-22

3.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

Review 4.  Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations.

Authors:  Joana Prata; Susana G Santos; Maria Inês Almeida; Rui Coelho; Mário A Barbosa
Journal:  J Neuroinflammation       Date:  2017-09-04       Impact factor: 8.322

5.  TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia.

Authors:  David R Goldsmith; Ebrahim Haroon; Andrew H Miller; Gregory P Strauss; Peter F Buckley; Brian J Miller
Journal:  Schizophr Res       Date:  2018-02-28       Impact factor: 4.939

Review 6.  The Gut-Brain Axis, BDNF, NMDA and CNS Disorders.

Authors:  Raeesah Maqsood; Trevor W Stone
Journal:  Neurochem Res       Date:  2016-08-23       Impact factor: 3.996

7.  The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis.

Authors:  M Morrens; C Overloop; V Coppens; E Loots; M Van Den Noortgate; S Vandenameele; M Leboyer; L De Picker
Journal:  Mol Psychiatry       Date:  2022-04-28       Impact factor: 15.992

Review 8.  The impact of inflammation on neurocognition and risk for psychosis: a critical review.

Authors:  Sophia Kogan; Luz H Ospina; Vijay A Mittal; David Kimhy
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-10-16       Impact factor: 5.270

9.  Sex differences in TGFB-β signaling with respect to age of onset and cognitive functioning in schizophrenia.

Authors:  Dorota Frydecka; Błażej Misiak; Edyta Pawlak-Adamska; Lidia Karabon; Anna Tomkiewicz; Paweł Sedlaczek; Andrzej Kiejna; Jan Aleksander Beszłej
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-05       Impact factor: 2.570

10.  The effect of deficient muscarinic signaling on commonly reported biochemical effects in schizophrenia and convergence with genetic susceptibility loci in explaining symptom dimensions of psychosis.

Authors:  Costa Vakalopoulos
Journal:  Front Pharmacol       Date:  2014-12-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.